This course has been run annually for the past seventeen years. It encompasses reviews and updates in the managementofmedicalproblemsthatobstetricphysicians and obstetricians can encounter in their practice. There were120delegatestothiscoursefromdifferentcountries around the world. Over three days, internationally renownedexpertsinobstetricmedicineconsideredawide rangeoftopicssuchasthyroiddiseaseandotherendocrine disorders, connective tissue disorders, diabetes, sickle cell disease, asthma, neurology disorders, renal diseases and heart diseases. We chose to reflect on some of the endocrine-relatedtopicstopresentabriefsummaryrather thangothroughthefullcurriculum.
Introduction
Medical disorders in pregnant women are particularly seriouslyviewedbybothobstetriciansandphysicians.This lead to the development of a highly specialized medical subspecialty namely "Obstetric Medicine". Practitioners in this field are required to have a good base of general medicineinadditiongoodin-depthknowledgeofthelimits of physiological changes during pregnancy. CAT (Controlled Antenatal Thyroid Screening) study is an ongoing prospective randomized controlled trials comparing"screeningplustreating"versus"noscreening". TherewasnodifferenceinaverageIQbutthosewhowere treatedhadbetterIQscore>85.
There is insufficient evidence for universal screening. However screening is recommended in high risk groups (Table2)(2).
Postpartum Thyroiditis
Postpartum thyroiditis (PPT) is caused by destructive autoimmune lymphocytic thyroiditis and is associated withTPO(thyroidperioxidase)positiveantibodies.IfTPO antibodies are present, the risk of thyroiditis is 50-80% of pregnancies. Recurrence risk is about 70 % in future pregnancy.Mostpatientsdorecoverspontaneously.
Finally,itwasstressedthatthyroiddisordersareassociated with adverse pregnancy outcomes if untreated. But if diagnosed early and treated adequately, the outcome is goodandunaffectedbythediseaseprocess.
Other Endocrine Disorders
Professor Catherine Williamson, covered collectively a number of endocrine disorders under the title other endocrine disorders. The following three topics were covered.
Vitamin D Deficiency
ThereisanincreaseinincidenceofvitaminDdeficiency among pregnant women.The presented data showed that halfofnonEuropeanethnicgrouphadvitaminDlevelsless than20nmol/LinastudyfromCardiff(3).Similardatafrom aDutchstudy(n=358)where59%ofnonwesternpregnant womenhadVitaminDlevelsbelow25nmol/L(4).Maternal vitaminDdeficiencyhasimplicationsonthewomenand herfetus.Theclassicmaternalconsequencesareboneloss, mildhypocalcaemia,secondaryhyperparathyroidismandin severecasesosteomalaciaandmyopathy.Thereisevidence from the literature regarding association of vitamin D deficiency with increased risk of pre-eclampsia, impaired glucose homeostasis and gestational diabetes (5) . With regards to the fetal consequences bone effects are noted withreducedfetalfemoralgrowth,neonatalcordcalcium levels,skeletalmineralizationandbonemass,increaserate of craniotabes (22%). From animal and epidemiological studies there are other adverse neonatal outcomes from fetalvitaminDdeficiencywithincreasedriskoflearning difficulties,memorydisorders,type1diabetesandasthma. Inviewoftheseconsequences,vitaminDsupplementation isessentialinpregnancyandtheUKEndocrinesociety's latest guideline 2011 states that pregnant and lactating women require at least 600 IU vitamin D per day, to maintain a blood level over 30nmol/L at least 1500-2000 IUvitaminDsupplementationperdayisrequiredandfor breast milk fed infants the mother requires at least 4000-6000IU of vitamin D a day (6) . There are no adverse outcomes associated with supplementation of vitamin D atadoseof400-4000IUperdayasreportedfromarecent randomisedcontroltrialwith494pregnantwomen.Most studiesshowingtheteratogenicityofvitaminDdeficiency arefromanimalstudiesandthe2humanstudiesareinthe context of treatment of hyperparathyroidism where the averagedoseofvitaminDwas100,000IUaday (8) .Prof.
Williamson advised to supplement all pregnant women with 400-800 IU per day, and recommended to recheck serumcalciumandvitaminDifdeficienttoconsiderhigher doseslike20,000IUperweekfor4weeks(9).
Parathyroid disease
There are physiological changes in pregnancy that decrease the effect hypercalcemia in women with hyperparathyroidism. These changes include an increase urinaryexcretionofcalcium,hypoalbunimia,andtransfer totheuteroplacentalunithencemostpregnantwomen withhyperparathyroidismareasymptomatic.Somewomen do present with nephrolithiasis but the most common feature encountered in pregnancy is hypertension, hence young women in the reproductive age with unexplained hypertensionshouldbescreenedforhyperparathyroidism. Thereis40-50%perinatalcomplicationrateassociatedwith hyperparathyroidisminpregnancy.Fetallossandneonatal tetanyarethecommonestoftheseperinatalcomplication from a single centre study (9) . Parathyroidectomy is the treatment of choice for most cases with hypercalcemia, as fetal loss is seen in all levels of hypercalcemia. Timing of surgery should be in the second trimester . Parathyroidectomy may be challenging in pregnancy whenmedastinalexplorationmayberequiredwhichisnot recommendedinpregnancy.Increaseoffluidintaketo3L perdaymaybeanoptiontodecreasethecalciumlevelsin patientwithmoderatelevel (10) .AstudyfromSwedenhas shownthatwomenwithparathyroidadenomasareathigher riskofpreeclampsia (11) .Itisalsoimportanttoconsider familyhistoryinwomenwithprimaryhyperparathyroidism therefore need to screen for multiple endocrine neoplasia type1andtype2(MEN1andMEN2respectively),familial hyperparathyroidismandjawtumours.
Pituitary tumours
Inpregnancythereisanincreaseintheprolactinsecretion thereforemeasuringserumprolactinlevelsinpregnancyhas novalueinmonitoringprolactinomas (12, 13) .Studieshave shown that is acceptable to stop dopamine agonist with review in each trimester in women with microadenomas as it has been noted that microprolactinoma enlargement in only 2.5% of cases while macroprolactinoma 29.6% enlarge.Incontrastwithmacroadenomaswhencontinuing oftreatmentandcarefullymonitoringforsignsoftumour expansionisadvisable.Bothbromocriptineandcabergoline aresafetouseinpregnancyfromvariousstudiesdespitethe theoreticalriskofcardiacfibrosiswithcabergolinethatwas seenwithhighdosesinthetreatmentofParkinsondisease (14, 15) .Newerdrugslikequinagolidehasa5%fetalrisk of malformation. During breast feeding cabergoline and bromocriptine must be stopped and to reassure women that breast feeding does not increase the size of pituitary tumours (16) (17) .
